Jennifer Go

MSc, BHSc

Risk Analyst, Epidemiologist

Joined RSI in 2017

  • Canada

    Country of Residence

Jennifer Go

Personal Introduction

I completed my BHSc in Health Sciences at the University of Ottawa, where I was exposed to a wide variety of disciplines, contributing to my understanding of the value of interdisciplinary approaches and collaboration in conducting health research. My honours thesis focused on the development of effective methodology and data analysis techniques to assess the relationship between genomic methylation and the silencing of genes believed to be related to the manifestation of binge eating disorder. This research project was an enriching experience that expanded my knowledge on mental illness in relation to epigenetics. I found an interest in epidemiological research at the EndoTox Laboratory, where I worked on the analysis of a moderate-sized dataset containing information collected for a case-control study on cancer patients. From this experience, I became more familiar with data cleaning procedures, and conducting statistical tests.

I earned my MSc in Epidemiology at the University of Ottawa, where the program covered a wide range of topics, enhancing my analytical skills and contributing to my ability to program using SAS. In my second year of the master’s program, I was a teaching assistant for the graduate course, Introductory Epidemiology, where I had the opportunity to lead weekly group discussions, helping students to think critically when evaluating the quality of research, as well as reinforcing their understanding of basic epidemiological concepts and methods.

My master’s thesis focused on the effects of gestational exposure to environmental phthalates on maternal and perinatal outcomes, as well as the role of inflammatory biomarkers as potential mediators. Specifically, this included a systematic review, and two analyses using data from the Maternal-Infant Research on Environmental chemicals (MIREC) study.

Jennifer Go at seminar

"Some of us,
are born to love numbers...
I guess I'm one of those people."

Jennifer Go: Current Focus

Jennifer joined RSI in August of 2017 as a Risk Analyst with specialization in epidemiology. She possesses a diverse set of skills that contributes to her flexibility to work on a wide range of scientific projects. In particular, Jennifer has research experience in conducting systematic reviews, manipulating large datasets, and constructing statistical models. To date, she has been involved with a number of literature reviews on various topics, including the association of parabens with reproductive and endocrine effects, the potential therapeutic benefits of cannabis use during active cancer treatment, and the pharmacoeconomic evaluation of botulinum toxin type A products for select indications.

Her expertise in quantitative epidemiology has allowed her to engage in a number of activities involving data from various sources, including electronic health records and questionnaires. In particular, Jennifer has worked with a team of analysts, to develop and test multiple approaches to accurately import datasets of substantial sizes into SAS. She has also performed analyses to examine medication use trends and the distribution of disease using electronic health records from the Cerner Health Facts database, and has generated reports to identify signals associated with pharmaceutical products using data from the FDA Adverse Event Reporting System (FAERS). As well, Jennifer has analyzed self-reported data collected by questionnaires to calculate the proportion of disease (e.g. high blood pressure, heart disease, etc.) among participants who have potentially been exposed to salt contaminated water on an Indian reserve.

Works and Accomplishments

Selected Reports

  • Occupational Exposure Tools used for Risk Assessment by International Regulatory Agencies. Report prepared for Health Canada. January 2020.
  • Clinical Drug Review for WSIB Formulary Consideration: Botulinum Toxin. Report prepared for Workplace Safety Insurance Board. May 2019.
  • Rapid Review of Evidence on Therapeutic Benefits of Cannabis During Cancer Treatment. Report prepared for the Canadian Partnership Against Cancer. March 2019.
  • Comparative Analysis of High-Throughput Exposure Models. Report prepared for Health Canada. October 2018.
  • Evidence Synthesis on Factors Associated with Abnormal Call Rate in Breast Cancer Screening. Report prepared for the Canadian Partnership Against Cancer. June 2018.

Jennifer Go: Extra-curricular

Jennifer enjoys solving puzzles, going biking, and doing yoga.

Please enter your name.
Please enter a subject.
Please enter a message.
Please check the captcha to verify you are not a robot.
  • 0%

    99% of our added value is our staff.

RSIepidemiologiststoxicologistsmedical doctorsengineersprogrammerssoftware engineerseditorstranslatorscampaignerscommunicatorsperception analystspolicy expertsregulatory advisorschemistsbiologistsclimate expertsurban expertspublic health specialistsmathematicianstrainers

Daniel Krewski

Dr. Krewski serves as Chief Risk Scientist and CEO of Risk Sciences International. He also holds academic appointments as Professor in the School of Epidemiology and Public Health and Scientific Director of the McLaughlin Centre for Population Health Risk Assessment in the Faculty of Medicine at the University of Ottawa. Dr. Krewski is a Fellow of the Society of Risk Analysis and the American Statistical Association, and a lifetime National Affiliate of the US National Academy of Sciences. In 2013, he received the Distinguished Achievement Award from the Society for Risk Analysis, for excellent performance in the practice of risk analysis. He has contributed to over 900 scientific and technical publications in the field of risk science during the course of his career to date.

Full Bio...

Emma Hartnett

Dr. Hartnett currently works on the development of risk-based decision-making processes and tools to support public risk assessment. Current focus includes: working with the Canadian Food Inspection Agency exploring methodologies to support risk-based monitoring of contaminants in food; working with Transport Canada to develop guidelines and methodologies to support risk-based decisions related to public risks from the transportation system; working with the U.S. Food and Drug Administration on continuing expansions and improvements to the FDA-iRISK tool.

Full Bio...

Natalia (Natasha) Shilnikova

At RSI, Dr. Natalia (Natasha) Shilnikova has been working on projects involving toxicology, epidemiology and human health risk assessment, such as development of toxicity profiles for several chemicals on Health Canada’s Domestic Substances List (DSL); a systematic review of potential cancer and reproductive risks of artificial sweeteners for the International…

Full Bio...

Todd Ruthman

Todd Ruthman’s current focus is on tools that help regulators visualize and understand the public risk burden within their mandates to help inform risk-based decisions. Mr. Ruthman provides design, management, modelling, coding, and database development expertise for these tools. Mr. Ruthman also manages the RSI development group enhancing previously released tools…

Full Bio...

Martin LeBlanc

Mr. Martin LeBlanc is responsible for growing RSI’s book of business, supporting all activities to this end. His line is always open to assist clients old and new. He strives to understand and provide a client’s unique need on a project, having done so for many government and private clients across the health, nuclear, power generation, aerospace, manufacturing, transportation and national defence sectors.

Full Bio...

Anne Wiles

For her work at RSI, Anne has built on her previous experience and academic research through work on communication on nuclear power and nuclear waste disposal; developing communication strategies and messaging on health risk issues; and delivering training on risk communication. She has also applied her familiarity with risk regulation in many projects on government…

Full Bio...

Siva Ramoju

Siva Ramoju holds Masters Degrees in Biotechnology as well as Cellular Toxicology. His previous and present work in cellular toxicology has provided him with training and research experience in understanding how chemicals can damage individual cells, and an understanding of toxicity from the perspective of the whole animal.

Full Bio...

Greg Paoli

As RSI’s Principal Risk Scientist and COO, Greg Paoli is currently working with a broad spectrum of clients in the public and private sectors, with the greatest emphasis on the development of new approaches to transform regulatory systems to be more “risk-based” at multiple levels: how senior decision-makers process risk information and make the “tough choices” in regulating health and safety, how an organization can optimize its resources across a diverse mandate to maximize total “portfolio-level” risk reduction, and how to operationalize key resources like the scheduling of inspections when faced with thousands of inspection targets, but not enough resources to inspect all of them.

Full Bio...

Franco Momoli

Dr. Momoli is the acting Practice Lead for Chemical and Product Safety at Risk Sciences International, as well as an adjunct professor in the School of Epidemiology and Public Health at the University of Ottawa.

Full Bio...

Nataliya Karyakina

Dr. Nataliya Karyakina has solid knowledge and extensive experience in hazard identification and human health risk assessments of toxic chemicals present in air, water, food and consumer products. Her research focuses on multidisciplinary studies of potential adverse health effects.

Full Bio...

Cemil ‘Jim’ Alyanak

Now serving as RSI’s Vice-President Communications and Strategic Initiatives, for years Cemil has provided organizations with guidance designed to transmit mission-critical messages. An anti-tobacco campaign is not about promoting a strategy, it’s about saving lives. Get the message wrong and people die. That type of commitment to results is what Cemil brings to Risk Sciences International.

Full Bio...

Donald Mattison

Dr. Donald Mattison was appointed Chief Medical Officer and Senior Vice President of Risk Sciences International in 2012. Dr. Mattison also serves as Associate Director of the McLaughlin Centre for Population Health Risk Assessment and as Adjunct Professor at the School of Epidemiology and Public Health at the University of Ottawa. He is also Medical Advisor to QuarterWatch: Monitoring FDA MedWatch Reports published by the Institute for Safe Medication Practices in Horsham, Pennsylvania.

Full Bio...

Hong Duan

Since joining RSI’s technical team in 2011, Hong has focused on developing risk-based database-driven web projects. Her extensive knowledge and experience, has helped RSI to develop high quality software for multiple clients including the Public Health Agency of Canada, the U.S. Food and Drug Administration, the Food and Agriculture Organization of the United Nations based in Rome, and the World Health Organization based in Geneva.

Full Bio...

Michael G. Tyshenko

Dr. Tyshenko is involved with various health risk issues and is the lead on chemical peer reviews at RSI. He continues international research on infectious disease health policy and evidence-based decision-making for SARS, MERS and COVID-19 with a collaborative working group from China, USA, and the UAE. Other ongoing work in Nepal with the Ministry of Health in collaboration…

Full Bio...